Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

Luca Laurenti; Idanna Innocenti; Robin Foa; Massimo Gentile; Tait D. Shanafelt; Francesca Romana Mauro; Gianluigi Reda; Davide Rossi; Maria Ilaria Del Principe; Giovanna Cutrona; Ilaria Angeletti; Marta Coscia; Yair Herishanu; Annalisa Chiarenza; Stefano Molica; Stefania Ciolli; Neta Goldschmidt; Francesco Angrilli; Annamaria Giordano; Angela Rago; Osnat Bairey; Giovanni Tripepi; Kari G. Chaffee; Parikh A. Sameer; Ernesto Vigna; Katja Zirlik; Lev Shvidel; Anna Grazia Recchia; Francesco Di Raimondo; Giovanni Del Poeta; Agostino Cortelezzi; Antonino Neri; Manlio Ferrarini; Gianluca Gaidano; Neil E. Kay; Aaron Polliack; Robin Foà; Fortunato Morabito

doi:10.1111/ejh.13149

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

Luca Laurenti, Idanna Innocenti, Robin Foa, Massimo Gentile, Tait D. Shanafelt, Francesca Romana Mauro, Gianluigi Reda, Davide Rossi, Maria Ilaria Del Principe, Giovanna Cutrona, Ilaria Angeletti, Marta Coscia, Yair Herishanu, Annalisa Chiarenza, Stefano Molica, Stefania Ciolli, Neta Goldschmidt, Francesco Angrilli, Annamaria Giordano, Angela RagoOsnat Bairey, Giovanni Tripepi, Kari G. Chaffee, Parikh A. Sameer, Ernesto Vigna, Katja Zirlik, Lev Shvidel, Anna Grazia Recchia, Francesco Di Raimondo, Giovanni Del Poeta, Agostino Cortelezzi, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Neil E. Kay, Aaron Polliack, Robin Foà, Fortunato Morabito

Risultato della ricerca: Contributo in rivista › Articolo in rivista

5 Citazioni (Scopus)

Abstract

An international collaboration has led to the development of a comprehensive tool [CLL‐IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL‐IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2‐microglobulin plasma levels, clinical stage, and age. CLL‐IPI provides the means to stratify CLL patients in the daily clinical practice (Table S1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL‐IPI on progression‐free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first‐line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016.

Lingua originale	English
pagine (da-a)	N/A-N/A
Rivista	European Journal of Haematology
DOI	https://doi.org/10.1111/ejh.13149
Stato di pubblicazione	Pubblicato - 2018

Keywords

CLL-IPI
PFS
chemo-immunotherapy
chronic lymphocytic leukemia
prognosis
progression-free survival

Accesso al documento

10.1111/ejh.13149

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Laurenti, L., Innocenti, I., Foa, R., Gentile, M., Shanafelt, T. D., Mauro, F. R., Reda, G., Rossi, D., Del Principe, M. I., Cutrona, G., Angeletti, I., Coscia, M., Herishanu, Y., Chiarenza, A., Molica, S., Ciolli, S., Goldschmidt, N., Angrilli, F., Giordano, A., ... Morabito, F. (2018). Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. European Journal of Haematology, N/A-N/A. https://doi.org/10.1111/ejh.13149

@article{bab4c3c1f65b405db786dbfdcb63ee84,

title = "Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment",

abstract = "An international collaboration has led to the development of a comprehensive tool [CLL‐IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL‐IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2‐microglobulin plasma levels, clinical stage, and age. CLL‐IPI provides the means to stratify CLL patients in the daily clinical practice (Table S1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL‐IPI on progression‐free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first‐line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016.",

keywords = "CLL-IPI, PFS, chemo-immunotherapy, chronic lymphocytic leukemia, prognosis, progression-free survival, CLL-IPI, PFS, chemo-immunotherapy, chronic lymphocytic leukemia, prognosis, progression-free survival",

author = "Luca Laurenti and Idanna Innocenti and Robin Foa and Massimo Gentile and Shanafelt, {Tait D.} and Mauro, {Francesca Romana} and Gianluigi Reda and Davide Rossi and {Del Principe}, {Maria Ilaria} and Giovanna Cutrona and Ilaria Angeletti and Marta Coscia and Yair Herishanu and Annalisa Chiarenza and Stefano Molica and Stefania Ciolli and Neta Goldschmidt and Francesco Angrilli and Annamaria Giordano and Angela Rago and Osnat Bairey and Giovanni Tripepi and Chaffee, {Kari G.} and Sameer, {Parikh A.} and Ernesto Vigna and Katja Zirlik and Lev Shvidel and Recchia, {Anna Grazia} and {Di Raimondo}, Francesco and {Del Poeta}, Giovanni and Agostino Cortelezzi and Antonino Neri and Manlio Ferrarini and Gianluca Gaidano and Kay, {Neil E.} and Aaron Polliack and Robin Fo{\`a} and Fortunato Morabito",

year = "2018",

doi = "10.1111/ejh.13149",

language = "English",

pages = "N/A--N/A",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "Oxford : Blackwell",

}

Laurenti, L, Innocenti, I, Foa, R, Gentile, M, Shanafelt, TD, Mauro, FR, Reda, G, Rossi, D, Del Principe, MI, Cutrona, G, Angeletti, I, Coscia, M, Herishanu, Y, Chiarenza, A, Molica, S, Ciolli, S, Goldschmidt, N, Angrilli, F, Giordano, A, Rago, A, Bairey, O, Tripepi, G, Chaffee, KG, Sameer, PA, Vigna, E, Zirlik, K, Shvidel, L, Recchia, AG, Di Raimondo, F, Del Poeta, G, Cortelezzi, A, Neri, A, Ferrarini, M, Gaidano, G, Kay, NE, Polliack, A, Foà, R & Morabito, F 2018, 'Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment', European Journal of Haematology, pagg. N/A-N/A. https://doi.org/10.1111/ejh.13149

TY - JOUR

T1 - Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

AU - Laurenti, Luca

AU - Innocenti, Idanna

AU - Foa, Robin

AU - Gentile, Massimo

AU - Shanafelt, Tait D.

AU - Mauro, Francesca Romana

AU - Reda, Gianluigi

AU - Rossi, Davide

AU - Del Principe, Maria Ilaria

AU - Cutrona, Giovanna

AU - Angeletti, Ilaria

AU - Coscia, Marta

AU - Herishanu, Yair

AU - Chiarenza, Annalisa

AU - Molica, Stefano

AU - Ciolli, Stefania

AU - Goldschmidt, Neta

AU - Angrilli, Francesco

AU - Giordano, Annamaria

AU - Rago, Angela

AU - Bairey, Osnat

AU - Tripepi, Giovanni

AU - Chaffee, Kari G.

AU - Sameer, Parikh A.

AU - Vigna, Ernesto

AU - Zirlik, Katja

AU - Shvidel, Lev

AU - Recchia, Anna Grazia

AU - Di Raimondo, Francesco

AU - Del Poeta, Giovanni

AU - Cortelezzi, Agostino

AU - Neri, Antonino

AU - Ferrarini, Manlio

AU - Gaidano, Gianluca

AU - Kay, Neil E.

AU - Polliack, Aaron

AU - Foà, Robin

AU - Morabito, Fortunato

PY - 2018

Y1 - 2018

N2 - An international collaboration has led to the development of a comprehensive tool [CLL‐IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL‐IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2‐microglobulin plasma levels, clinical stage, and age. CLL‐IPI provides the means to stratify CLL patients in the daily clinical practice (Table S1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL‐IPI on progression‐free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first‐line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016.

AB - An international collaboration has led to the development of a comprehensive tool [CLL‐IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL‐IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2‐microglobulin plasma levels, clinical stage, and age. CLL‐IPI provides the means to stratify CLL patients in the daily clinical practice (Table S1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL‐IPI on progression‐free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first‐line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016.

KW - CLL-IPI

KW - PFS

KW - chemo-immunotherapy

KW - chronic lymphocytic leukemia

KW - prognosis

KW - progression-free survival

KW - CLL-IPI

KW - PFS

KW - chemo-immunotherapy

KW - chronic lymphocytic leukemia

KW - prognosis

KW - progression-free survival

UR - http://hdl.handle.net/10807/135006

U2 - 10.1111/ejh.13149

DO - 10.1111/ejh.13149

M3 - Article

SP - N/A-N/A

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

ER -

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo